|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...3637383940414243444546...6768» |
- Imbruvica (ibrutinib) / AbbVie, J&J
New P1 trial: Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (clinicaltrials.gov) - Apr 7, 2014
P1, N=78, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| Octagam (intravenous normal human immunoglobulin) / Octapharma
Trial initiation date: Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults (clinicaltrials.gov) - Apr 6, 2014
P3, N=116, Completed, Sponsor: Octapharma
Initiation date: Jan 2006 --> Jun 2006
- Trial initiation date: Comprehensive Frailty Assessment (clinicaltrials.gov) - Apr 6, 2014
P=N/A, N=400, Recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Initiation date: Jan 2006 --> Jun 2006 Initiation date: Dec 2013 --> Apr 2014
- Enrollment open: Comprehensive Frailty Assessment (clinicaltrials.gov) - Apr 6, 2014
P=N/A, N=400, Recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Initiation date: Dec 2013 --> Apr 2014 Not yet recruiting --> Recruiting
- | Rebinyn (nonacog beta pegol) / Novo Nordisk
Trial completion: paradigm™ 4t: Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 (clinicaltrials.gov) - Apr 6, 2014
P3, N=71, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Inrebic (fedratinib) / BMS
Enrollment change: Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly (clinicaltrials.gov) - Apr 6, 2014
P2, N=8, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed N=20 --> 8
- ||| Darzalex IV (daratumumab) / J&J
Clinical: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma (clinicaltrials.gov) - Apr 6, 2014
P1/2, N=112, Recruiting, Sponsor: Genmab
N=20 --> 8 N=78 --> 112
- || Avastin (bevacizumab) / Roche
New P2/3 trial: ALEGORI: Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) (clinicaltrials.gov) - Apr 6, 2014
P2/3, N=80, Recruiting, Sponsor: Hospices Civils de Lyon
- ||| bortezomib / Generic mfg., melphalan / Generic mfg.
Enrollment closed: Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Apr 6, 2014
P1/2, N=69, Active, not recruiting, Sponsor: Mayo Clinic
N=78 --> 112 Not yet recruiting --> Active, not recruiting
- Inrebic (fedratinib) / BMS
Trial completion: Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly (clinicaltrials.gov) - Apr 6, 2014
P2, N=8, Completed, Sponsor: Sanofi
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Enrollment open: ALEGORI: Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) (clinicaltrials.gov) - Apr 2, 2014
P2/3, N=80, Recruiting, Sponsor: Hospices Civils de Lyon
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | marizomib (NPI-0052) / Triphase Accelerator Corporation, BMS
Clinical: Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 1, 2014
P1, N=36, Not yet recruiting, Sponsor: Triphase Research and Development I Corporation
- |||||| Anathromb (anagrelide CR) / AOP Orphan Pharma
Enrollment open: TEAM-ET: Anagrelide Retard in Essential Thrombocythemia (clinicaltrials.gov) - Apr 1, 2014
P3, N=100, Recruiting, Sponsor: AOP Orphan Pharmaceuticals AG
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- dexamethasone / Generic mfg., thalidomide / Generic mfg.
Trial completion: Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Apr 1, 2014
P3, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Doptelet (avatrombopag) / SOBI
Trial completion: Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) (clinicaltrials.gov) - Mar 30, 2014
P3, N=49, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Studies of Heritable Disorders of Connective Tissue (clinicaltrials.gov) - Mar 28, 2014
P=N/A, N=1335, Completed, Sponsor: National Institute on Aging (NIA)
Active, not recruiting --> Completed N=1835 --> 1335
- ||| Zelboraf (vemurafenib) / Roche
Enrollment change: A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers (clinicaltrials.gov) - Mar 26, 2014
P2, N=160, Recruiting, Sponsor: Hoffmann-La Roche
N=1835 --> 1335 N=101 --> 160
- Cytovene (ganciclovir) / Roche
Enrollment change: Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant (clinicaltrials.gov) - Mar 26, 2014
P2, N=61, Completed, Sponsor: City of Hope Medical Center
N=101 --> 160 N=24 --> 61
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion, Metastases: Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies (clinicaltrials.gov) - Mar 26, 2014
P=N/A, N=152, Completed, Sponsor: University of Illinois at Chicago
N=24 --> 61 Active, not recruiting --> Completed
- TevaGrastim (filgrastim biosimilar) / Nippon Kayaku, Teva, Mozobil (plerixafor) / Sanofi
Combination therapy, Head-to-Head: Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 25, 2014
P=N/A, N=100, Not yet recruiting, Sponsor: Washington University School of Medicine
- bortezomib / Generic mfg., dexamethasone / Generic mfg., bendamustine / Generic mfg.
Enrollment closed: Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy (clinicaltrials.gov) - Mar 25, 2014
P2, N=42, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| esomeprazole / Generic mfg.
Trial completion: Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation (clinicaltrials.gov) - Mar 25, 2014
P=N/A, N=369, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial initiation date: Control of Major Bleeding After Trauma Study (clinicaltrials.gov) - Mar 24, 2014
P2, N=150, Not yet recruiting, Sponsor: Denver Health and Hospital Authority
Active, not recruiting --> Completed Initiation date: Oct 2013 --> Apr 2014
- ||| bortezomib / Generic mfg.
Enrollment closed: Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant (clinicaltrials.gov) - Mar 24, 2014
P2, N=150, Active, not recruiting, Sponsor: Mayo Clinic
Initiation date: Oct 2013 --> Apr 2014 Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Roche
Trial completion: PROLONG: Rituximab as Second Line Treatment for ITP (clinicaltrials.gov) - Mar 24, 2014
P3, N=112, Completed, Sponsor: Ostfold Hospital Trust
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Enrollment change: VIP: The Von Willebrand Disease (VWD) International Prophylaxis Study (clinicaltrials.gov) - Mar 23, 2014
P=N/A, N=105, Completed, Sponsor: Skane University Hospital
Active, not recruiting --> Completed N=13 --> 105
- Trial completion: Hemophilia Inhibitor Genetics Study (HIGS) (clinicaltrials.gov) - Mar 23, 2014
P=N/A, N=1137, Completed, Sponsor: Skane University Hospital
N=13 --> 105 Active, not recruiting --> Completed
- NovoSeven (eptacog alfa) / Novo Nordisk
Trial withdrawal: Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven (clinicaltrials.gov) - Mar 23, 2014
P1, N=0, Withdrawn, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- imetelstat (GRN163L) / Geron
Trial suspension: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (clinicaltrials.gov) - Mar 23, 2014
P2, N=40, Suspended, Sponsor: Geron Corporation
Not yet recruiting --> Withdrawn Active, not recruiting --> Suspended
- NovoSeven (eptacog alfa) / Novo Nordisk
Enrollment change: Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven (clinicaltrials.gov) - Mar 23, 2014
P1, N=0, Withdrawn, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Suspended N=24 --> 0
- | Farydak (panobinostat) / Secura Bio
Trial completion: Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma (clinicaltrials.gov) - Mar 23, 2014
P1/2, N=40, Completed, Sponsor: Oncotherapeutics
N=24 --> 0 Recruiting --> Completed
- peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma (clinicaltrials.gov) - Mar 23, 2014
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- lenalidomide / Generic mfg., tadalafil / Generic mfg.
Trial termination: Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma (clinicaltrials.gov) - Mar 22, 2014
P2, N=14, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Terminated; early stopping rule
- lenalidomide / Generic mfg.
Trial completion: Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 22, 2014
P2, N=40, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Terminated; early stopping rule Active, not recruiting --> Completed
- Clinical: Oligosecretary Myeloma: Prevalence and Its Clinical Significance (clinicaltrials.gov) - Mar 20, 2014
P=N/A, N=390, Completed, Sponsor: Samsung Medical Center
- | lenalidomide / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment open: Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 20, 2014
P1/2, N=45, Recruiting, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- New P2/3 trial: Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Mar 19, 2014
P2/3, N=12, Recruiting, Sponsor: Laboratoire français de Fractionnement et de Biotechnologies
- Trial termination, Post-transplantation: Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) - Mar 19, 2014
P1, N=1, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting --> Recruiting Completed --> Terminated; low accrual
- RG4733 / Roche
Enrollment change, Combination therapy: RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (clinicaltrials.gov) - Mar 19, 2014
P1, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; low accrual N=40 --> 30
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment change: Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers (clinicaltrials.gov) - Mar 19, 2014
P2, N=1, Completed, Sponsor: University of California, Davis
N=40 --> 30 N=20 --> 1
- Enrollment change, Post-transplantation: Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) - Mar 19, 2014
P1, N=1, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=20 --> 1 N=30 --> 1
- |||||||||| Abstilla (lonoctocog alfa) / CSL Behring
New P3 trial: Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A (clinicaltrials.gov) - Mar 19, 2014
P3, N=75, Not yet recruiting, Sponsor: CSL Behring
- cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Enrollment closed, Post-transplantation: Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer (clinicaltrials.gov) - Mar 19, 2014
P2, N=92, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=30 --> 1 Completed --> Active, not recruiting
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial completion: Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers (clinicaltrials.gov) - Mar 19, 2014
P2, N=1, Completed, Sponsor: University of California, Davis
Completed --> Active, not recruiting Active, not recruiting --> Completed
- Trial initiation date: PUCHS: Project to Update the Study of Congenital Haemophilia in Spain (clinicaltrials.gov) - Mar 18, 2014
P=N/A, N=2500, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Initiation date: Oct 2013 --> Mar 2014
- Enrollment open: PUCHS: Project to Update the Study of Congenital Haemophilia in Spain (clinicaltrials.gov) - Mar 18, 2014
P=N/A, N=2500, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Initiation date: Oct 2013 --> Mar 2014 Not yet recruiting --> Enrolling by invitation
- ||||||| plerixafor / Generic mfg.
Trial completion: Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients (clinicaltrials.gov) - Mar 18, 2014
P3, N=302, Completed, Sponsor: Genzyme, a Sanofi Company
Not yet recruiting --> Enrolling by invitation Active, not recruiting --> Completed
- | lenalidomide / Generic mfg.
Trial initiation date: Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide (clinicaltrials.gov) - Mar 18, 2014
P2, N=41, Recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Initiation date: Dec 2013 --> Mar 2014
- | lenalidomide / Generic mfg.
Enrollment open: Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide (clinicaltrials.gov) - Mar 18, 2014
P2, N=41, Recruiting, Sponsor: Mayo Clinic
Initiation date: Dec 2013 --> Mar 2014 Not yet recruiting --> Recruiting
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 18, 2014
P2, N=36, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting